G1 Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

G1 Therapeutics

01/11/2023 13:32

* G1 Therapeutics Inc  GTHX.OQ  reported a quarterly
adjusted loss
of 35 cents​​ per share for the quarter ended in September,
higher than the same quarter last year, when the company
reported EPS of -59 cents.  The mean expectation of six analysts
for the quarter was for a loss of 33 cents per share. Wall
Street expected results to range from -42 cents to -24 cents per
share.
    * Revenue fell 47.8% to $12.30 million from a year ago;
analysts
expected $14.23 million. 
    * G1 Therapeutics Inc's reported EPS for the quarter was a
loss
of 35 cents​.
    * The company reported a quarterly loss of $18.2 million.
    * G1 Therapeutics Inc shares had risen by 14.6% this
quarter and
lost 69.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 7.2%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for G1 Therapeutics
Inc is $9.50 
This summary was machine generated from LSEG data November 1 at
01:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.33          -0.35          Missed
 Jun. 30 2023      -0.22          0.14           Beat
 Mar. 31 2023      -0.64          -0.53          Beat
 Dec. 31 2022      -0.84          -0.73          Beat